Celea Therapeutics begins patient dosing in global phase 3 SURPASS-IPF trial of deupirfenidone to treat idiopathic pulmonary fibrosis: Boston Tuesday, July 14, 2026, 16:00 Hrs [IS ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary fibrosis (IPF). The main end point in the study was lung function based on ...
Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID 1) and deupirfenidone 825 mg TID and successfully demonstrated ...
Celea Therapeutics has secured $180m in financing to support the planned pivotal Phase III SURPASS-IPF clinical trial of deupirfenidone (LYT-100). Deupirfenidone is an investigational next-generation ...
PureTech Health’s (LSE:PRTC) founded entity, Celea Therapeutics, has enrolled the first patient in SURPASS-IPF, a global Phase 3 clinical trial designed to compare its investigational therapy, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prior to this trial, CS014 had positive outcomes in an ...
Deupirfenidone 825 mg TID monotherapy significantly slowed lung function decline versus placebo at 26 weeks in people with idiopathic pulmonary fibrosis (adjusted mean FVC difference 91 mL; p=0.02), ...
“Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to ...
(RTTNews) - Pliant Therapeutics, Inc. (PLRX) announced the discontinuation of its BEACON-IPF Phase 2b trial evaluating bexotegrast for the treatment of idiopathic pulmonary fibrosis or IPF following a ...
GR-0621 targets natural killer T cells, reducing inflammation and fibrosis in idiopathic pulmonary fibrosis (IPF). The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating ...
Hosted on MSN
Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved
Trevi plans to initiate two Phase III trials in IPF-related chronic cough, with the first trial starting in Q2 2026 and the second in the second half of 2026, and expects to provide top line data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results